top of page

Recapping #ASH23 with Syndax CEO Michael Metzger

Syndax's CEO reviews late breaking data on the menin inhibitor revumenib in KMT2A-rearranged leukemias and discusses axatilimab's GvHD data.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page